New drug combo takes on advanced cancers in early trial
NCT ID NCT06131398
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 16 times
Summary
This early-phase study tests an experimental drug called AMG 355, given alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 77 adults with certain cancers (like lung, colorectal, stomach, or melanoma) are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alliance for Multispecialty Research - Kansas City
Merriam, Kansas, 66204, United States
-
Asan Medical Center
Seoul, 138-736, South Korea
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Erasmus Medisch Centrum
Rotterdam, 3015 CE, Netherlands
-
Gustave Roussy
Villejuif, 94805, France
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, 08036, Spain
-
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, 08023, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Institut Bergonie
Bordeaux, 33076, France
-
Istituto Oncologico della Svizzera Italiana
Bellinzona, 6500, Switzerland
-
Kantonsspital Sankt Gallen
Sankt Gallen, 9007, Switzerland
-
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
Warsaw, 02-781, Poland
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 1Z5, Canada
-
Radboud Universitair Medisch Centrum
Nijmegen, 6525 GA, Netherlands
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229, United States
-
St Vincents Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-ku, Tokyo, 135-8550, Japan
-
The Queen Elizabeth Hospital
Woodville South, South Australia, 5011, Australia
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.